BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guo S, Gao S, Liu R, Shen J, Shi X, Bai S, Wang H, Zheng K, Shao Z, Liang C, Peng S, Jin G. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. FASEB J 2019;33:873-84. [PMID: 30091943 DOI: 10.1096/fj.201800617R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Roche S, O'Neill F, Murphy J, Swan N, Meiller J, Conlon NT, Geoghegan J, Conlon K, McDermott R, Rahman R, Toomey S, Straubinger NL, Straubinger RM, O'Connor R, McVey G, Moriarty M, Clynes M. Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. Int J Mol Sci 2020;21:E962. [PMID: 32024004 DOI: 10.3390/ijms21030962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cho SY. Patient-derived xenografts as compatible models for precision oncology. Lab Anim Res 2020;36:14. [PMID: 32461927 DOI: 10.1186/s42826-020-00045-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang Q, Guo H, Wang S, Ma Y, Chen H, Li H, Li J, Li X, Yang F, Qiu M, Zhao S, Wang J. A novel circular RNA, circXPO1, promotes lung adenocarcinoma progression by interacting with IGF2BP1. Cell Death Dis 2020;11:1031. [PMID: 33268793 DOI: 10.1038/s41419-020-03237-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Okada S, Vaeteewoottacharn K, Kariya R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019;8:E889. [PMID: 31412684 DOI: 10.3390/cells8080889] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
5 Zhang X, Hong J, Zhong L, Wu Q, Zhang S, Zhu Q, Chen H, Wei D, Li R, Zhang W, Zhang X, Wang G, Zhou X, Chen J, Kang Y, Zha Z, Duan X, Huang Y, Sun C, Kong X, Zhou Y, Chen Y, Ye X, Feng Q, Li S, Xiang T, Gao S, Zeng MS, Zheng Q, Chen Y, Zeng YX, Xia N, Xu M. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proc Natl Acad Sci U S A 2022;119:e2202371119. [PMID: 35917353 DOI: 10.1073/pnas.2202371119] [Reference Citation Analysis]
6 Li H, Zhang LK, Li SF, Zhang SF, Wan WW, Zhang YL, Xin QL, Dai K, Hu YY, Wang ZB, Zhu XT, Fang YJ, Cui N, Zhang PH, Yuan C, Lu QB, Bai JY, Deng F, Xiao GF, Liu W, Peng K. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Cell Res 2019;29:739-53. [PMID: 31444469 DOI: 10.1038/s41422-019-0214-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
7 Suri R, Zimmerman JW, Burkhart RA. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. Ann Pancreat Cancer 2020;3:17. [PMID: 33889840 DOI: 10.21037/apc-20-29] [Reference Citation Analysis]
8 Zhu QY, Shan S, Yu J, Peng SY, Sun C, Zuo Y, Zhong LY, Yan SM, Zhang X, Yang Z, Peng YJ, Shi X, Cao SM, Wang X, Zeng MS, Zhang L. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nat Commun 2021;12:6624. [PMID: 34785638 DOI: 10.1038/s41467-021-26912-6] [Reference Citation Analysis]
9 Xu X, Gu H, Li H, Gao S, Shi X, Shen J, Li B, Wang H, Zheng K, Shao Z, Cheng P, Cha Z, Peng S, Nie Y, Li Z, Guo S, Qian B, Jin G. Large-cohort humanized NPI mice reconstituted with CD34+ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. FASEB J 2022;36:e22244. [PMID: 35262964 DOI: 10.1096/fj.202101548RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li Z, Zheng W, Wang H, Cheng Y, Fang Y, Wu F, Sun G, Sun G, Lv C, Hui B. Application of Animal Models in Cancer Research: Recent Progress and Future Prospects. Cancer Manag Res 2021;13:2455-75. [PMID: 33758544 DOI: 10.2147/CMAR.S302565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang CF, Shi XJ. Generation and application of patient-derived xenograft models in pancreatic cancer research. Chin Med J (Engl) 2019;132:2729-36. [PMID: 31725451 DOI: 10.1097/CM9.0000000000000524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Tang F, Wei Y, Zhang S, Wang J, Gu W, Tang F, Peng X, Wei Y, Liu J, Chen W, Zhang S, Gu L, Li Y. Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer. Front Oncol 2022;12:925671. [DOI: 10.3389/fonc.2022.925671] [Reference Citation Analysis]